TNFRSF17 and Miyoshi myopathy: Interestingly, BCMA antibody‐drug conjugate, anti‐BCMA Chimeric Antigenic Receptor‐T cells (CAR‐T cells) therapy, and bispecific BCMA‐directed CD3 T‐cell engager have shown impressive results in MM [8, 19].